- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05363267
NF-1, Nutraceutical Intervention
Studie av nutraceutical intervensjon med høy fenolisk ekstra jomfru olivenolje og curcumin for nevrofibromatose, type 1 (NF1)
The treatment plan is identical for all participants with the exception of the curcumin dose level that is assigned at study enrollment. Participants are instructed to take the curcumin and olive oil one after the other (order does not matter) twice a day on an empty stomach ideally 30 minutes before breakfast and dinner.
Curcumin and high phenolic extra virgin olive oil (HP-EVOO) may continue for up to 12 months in the absence of unacceptable side effects.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- NF1 diagnosis based on NIH Consensus Conference Criteria and/or genetic testing
- Measurable cutaneous neurofibromas (cNFs) with or without plexiform NF
- Aged 18 years or older at the time of written consent
- Voluntary signed written consent obtained before the performance of any study-related procedure not part of normal medical care
Exclusion Criteria:
- Concurrent treatment with selumetinib or other MAPK, MEK or mTOR inhibitors, other targeted therapies, chemotherapy or radiation
- Conditions requiring systemic immunosuppression
- Swallowing difficulties or strong gag reflex which may interfere with study compliance
- Any comorbidities that may affect study participation in the judgement of enrolling investigator
- Psychiatric illness, cognitive challenges, social situations, or other circumstances that would limit compliance with study requirements, per judgment of the enrolling investigator
- Treatment with high phenolic olive oil or curcumin within six months of study entry
- Known pregnancy or anticipated conception during the 1 year study period
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Curcumin with high phenolic extra virgin olive oil (HP-EVOO)
Identical for all participants with the exception of the curcumin dose level, which is assigned at study enrollment. |
identical for all participants with the exception of the curcumin dose level Dose 1: 1000 mg Curcumin daily dose with 1 capsule and 25 ml HP-EVOO volume at morning and night Dose 2: 2000 mg Curcumin daily dose with 2 capsules and 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules and 25 ml HP-EVOO volume at morning and night
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary objective of this study is to establish the safety and preliminary activity of curcumin and oleocanthal-rich olive oil supplementation in adult NF-1 persons with cutaneous neurofibromas.
Tidsramme: End of treatment (12 months)
|
The safety of this supplementation will be measured by the incidence of unacceptable/dose limiting toxicity (DLT) as defined any new Grade 2 or greater toxicity (based on CTCAE v 5). |
End of treatment (12 months)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Characterize the toxicities associated with the planned intervention
Tidsramme: 4 weeks after 1st dose of curcumin
|
Incidence of unacceptable/dose limiting toxicity defined as any new ≥Grade 2 toxicity (based on CTCAE v 5) that cannot be attributed to the disease under treatment or other reason. |
4 weeks after 1st dose of curcumin
|
|
To evaluate the effect of the intervention on BMI
Tidsramme: End of Treatment (12 months)
|
The BMI will be measures across dose level group 95% confidence intervals. |
End of Treatment (12 months)
|
|
To evaluate the effect of the intervention on lipid panel
Tidsramme: End of Treatment (12 months)
|
The lipid panel will be measures across dose level group 95% confidence intervals. |
End of Treatment (12 months)
|
|
To assess the effect of the intervention on quality of life
Tidsramme: End of treatment (12 months)
|
Focused on skin related morbidity and pain will be evaluated using the average and range of SkinDex scale (0-100) |
End of treatment (12 months)
|
|
To determine preliminary efficacy of the intervention
Tidsramme: End of treatment (12 months)
|
Measure the volumetric measurement of target plexiform neurofibroma (% difference from baseline will be reported) |
End of treatment (12 months)
|
|
To identify issues with compliance to the planned intervention
Tidsramme: End of treatment (12 months)
|
Incidence of study deviations |
End of treatment (12 months)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Clay Hoerig, MD, Masonic Cancer Center, Univeristy of Minnesota
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Neoplasmer
- Nevromuskulære sykdommer
- Genetiske sykdommer, medfødte
- Sykdommer i det perifere nervesystemet
- Neoplasmer etter histologisk type
- Nevrodegenerative sykdommer
- Neoplasmer, nervevev
- Heredodegenerative lidelser, nervesystemet
- Neoplasmer i nerveskjede
- Neoplastiske syndromer, arvelig
- Nevrokutane syndromer
- Nevrofibrom
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Nevrofibromatoser
- Nevrofibromatose 1
- Organiske kjemikalier
- Hydrokarboner, acyklisk
- Hydrokarboner
- Hydrokarboner, syklisk
- Hydrokarboner, aromatisk
- Diarlheptanoider
- Heptanes
- Alkaner
- Katekoler
- Fenoler
- Benzenderivater
- Curcumin
Andre studie-ID-numre
- 2021LS032
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .